Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,890.66 +13.61 (+0.17%) Bitcoin USD
64,585.00 +651.79 (+1.02%) CMC Crypto 200
1,373.36 +60.74 (+4.86%)
Tandem Diabetes Care, Inc. (0M0F.L)
| Previous close | 31.84 |
| Open | 30.72 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 30.72 - 30.79 |
| 52-week range | 13.89 - 43.04 |
| Volume | |
| Avg. volume | 681 |
| Market cap | 17.43M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | 3.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
SAN DIEGO, April 09, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results.
- GlobeNewswire
Parexel Announces CEO Succession Plan
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the c
- Business Wire
Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
SAN DIEGO, March 06, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previous
